CMMB Stock — Chemomab Therapeutics Ltd.: Cash, EV, Pipeline

Share price

$2.61

Market cap

$18.9M

Cash

$7.6M

Enterprise value

$11.3M

Balance sheet

Cash	$7.6M
Debt	$0.0M
Net cash	$7.6M
Enterprise value	$11.3M
Basic shares	7.2M shares
Fully diluted shares	43.9M shares
Fully diluted market cap	$114.6M
Cash per share	$1.05

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading CMMB daily closes…

Loading price history…

Pipeline assets

CM-101

Phase 2 · Active Modality: monoclonal antibody

Target CCL24

Indications

Primary sclerosing cholangitis (PSC) (Phase 2)
Systemic sclerosis (SSc) (Phase 2)
NASH / liver fibrosis (Phase 2)

Catalysts

— second half of 2024

Status note Humanized monoclonal antibody targeting CCL24. Phase 2 study in PSC ongoing; Phase 2 ABATE trial in SSc enrolling (IND cleared Feb 21, 2023); Phase 2a liver fibrosis biomarker trial in NASH completed.

Per-asset detail extracted from the 10-Q filed 2023-05-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	80,000	no change	0.01%	2026-08-14
Ikarian Capital	51,793	no change	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CMMB — Chemomab Therapeutics Ltd.

Balance sheet

Price history

Pipeline assets

Institutional holders